Risk factors

Clinical stage biopharmaceutical company focusing on pain treatments and orphan diseases faces going concern doubts and material weaknesses in internal controls.

Relmada Therapeutics paused its primary drug candidate esmethadone and pivoted to early-stage candidates NDV-01 and Sepranolone.

Richmond Mutual Bancorporation faces substantial concentration risk in commercial, multi-family, construction, and lease-financing loans totaling hundreds of millions. Heavy reliance on external vendors, third-party loan participants, and technology platforms introduces significant operational and cybersecurity vulnerabilities. Extensive federal and state banking regulations and capital requirements heavily restrict operations and profitability.

SailPoint relies heavily on acquiring and retaining identity security customers, maintaining channel partner networks, and managing rapid business growth.

Stardust Power is a pre-revenue development stage company facing going concern doubts with an accumulated deficit of $52.62 million.

Septerna is a clinical-stage biotechnology company with 75 employees, focusing on endocrinology, immunology, and neurology programs like SEP-786. The company faces high regulatory hurdles, intense competition, and relies entirely on external funding and partnerships since generating no product revenue.

SkyAI is an early-stage medical device company facing multi-million dollar losses and zero revenue to date. The business depends entirely on successfully commercializing Securgard, Sologard, and Sharps Provensa safety syringes. Strict healthcare regulations, intellectual property protection, and substantial capital raising needs dominate the risk profile.

Dependence on lease and debt obligations tied to tenant revenues and airport ground leases dominate our business risk profile.

Sow Good faces severe revenue volatility and reliance on key retailers like Five Below and Kroger for its freeze-dried candy. Operations depend heavily on founders Ira and Claudia Goldfarb and a concentrated raw material supply chain. Product melting issues and quality control risks directly threatened 2024 results and brand reputation.

Spero Therapeutics relies heavily on the success, regulatory approval, and commercialization of its lead product candidate tebipenem HBr under a partnership with GSK.

Neuronetics faces high concentration risk, relying on its NeuroStar Advanced Therapy System and treatment sessions for revenue.

Shattuck Labs is a preclinical biotechnology company with a net loss of $75.4 million in 2024 and an accumulated deficit of $381.7 million. The business is heavily dependent on the clinical success and patent protection of its lead product candidate, SL-325, for inflammatory bowel disease. Operations face substantial dilution risks from equity raises, heavy reliance on third-party manufacturers, and complex intellectual property challenges.